May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Author Affiliations & Notes
  • H.G. Jensen
    Ophthalmology Clinical Res, Allergan Inc, Irvine, CA
  • I. Morrissey
    GR Micro Ltd, London, United Kingdom
  • D. De Rubeis
    GR Micro Limited, London, United Kingdom
  • R. Burnett
    Allergan Inc, High Wycombe, United Kingdom
  • Footnotes
    Commercial Relationships  H.G. Jensen, Allergan, Inc. E; I. Morrissey, Allergan, Inc. F; D. De Rubeis, Allergan, Inc. F; R. Burnett, Allergan, Inc. E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4984. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.G. Jensen, I. Morrissey, D. De Rubeis, R. Burnett; SURVEILLANCE OF EUROPEAN OCULAR BACTERIAL PATHOGEN SUSCEPTIBILITY TO GATIFLOXACIN AND COMPARATORS . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4984.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To compare the susceptibility of a variety of ocular pathogens to gatifloxacin and other antimicrobial agents. Methods: A total of 532 bacterial ocular pathogens from ten European sites in 6 countries collected during 2001 and 2002 were sent to a central laboratory for re–identification and minimum inhibitory concentration (MIC) determination for gatifloxacin (GAT), ciprofloxacin (CIP), ofloxacin (OFL), fusidic acid (FUS), gentamicin (GEN) and chloramphenicol (CHL) using the NCCLS agar dilution method. Results: Methicillin–susceptible S. aureus (MSSA) was the most common pathogen (23.1%), followed by H. influenzae (15.1%), S. pneumoniae (13.2%), P. aeruginosa (7.1%), Methicillin–resistant S. aureus (MRSA; 6.6%), S. epidermidis (5.1%), and other bacterial species (each <5% of total). The MIC90 (mg/L) for all 532 isolates was 2 for GAT, 8 for CIP & OFL, 32 for GEN, 64 for CHL, and >64 for FUS. GAT was the most potent antimicrobial against MSSA, S. pneumoniae and S. epidermidis and was equivalent to CIP, but superior to the other agents, against H. influenzae. The MIC90s of GAT and CIP were identical for P. aeruginosa. GAT was the most active fluoroquinolone and had moderate activity against MRSA, although less activity than FUS and GEN. Conclusions: The 4th–generation fluoroquinolone, gatifloxacin, is highly effective against a broad spectrum of bacterial pathogens commonly found in ocular infections.

Keywords: antibiotics/antifungals/antiparasitics • bacterial disease • conjunctivitis 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.